Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to -$3.0 million.

  • Lipocine's Free Cash Flow fell 539.45% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 392.91%. This contributed to the annual value of -$1.3 million for FY2024, which is 8896.12% up from last year.
  • As of Q3 2025, Lipocine's Free Cash Flow stood at -$3.0 million, which was down 539.45% from -$1.9 million recorded in Q2 2025.
  • Lipocine's Free Cash Flow's 5-year high stood at $9.0 million during Q4 2021, with a 5-year trough of -$7.0 million in Q3 2021.
  • Its 5-year average for Free Cash Flow is -$1.9 million, with a median of -$2.6 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 34414.95% in 2021, then tumbled by 18179.61% in 2025.
  • Over the past 5 years, Lipocine's Free Cash Flow (Quarter) stood at $9.0 million in 2021, then plummeted by 121.52% to -$1.9 million in 2022, then decreased by 4.95% to -$2.0 million in 2023, then surged by 183.28% to $1.7 million in 2024, then plummeted by 276.47% to -$3.0 million in 2025.
  • Its Free Cash Flow stands at -$3.0 million for Q3 2025, versus -$1.9 million for Q2 2025 and -$2.0 million for Q1 2025.